ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

ALVR AlloVir Inc

0.7855
-0.0309 (-3.78%)
11 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
AlloVir Inc NASDAQ:ALVR NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.0309 -3.78% 0.7855 0.731 0.815 0.8199 0.7752 0.8199 173,971 01:00:00

Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for Investors - Contact The Gross Law Firm

14/03/2024 10:10am

PR Newswire (US)


AlloVir (NASDAQ:ALVR)
Historical Stock Chart


From Mar 2024 to May 2024

Click Here for more AlloVir Charts.

NEW YORK, March 14, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of AlloVir, Inc..

The Gross Law Firm (PRNewsfoto/The Gross Law Firm)

Shareholders who purchased shares of ALVR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/allovir-inc-loss-submission-form/?id=70851&from=4 

CLASS PERIOD: March 22, 2022 to December 21, 2023

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the posoleucel Phase 3 Studies were unlikely to meet their primary endpoints; (ii) as a result, it was likely that the Company would ultimately discontinue the posoleucel Phase 3 studies; (iii) accordingly, AlloVir overstated the efficacy and clinical and/or commercial prospects of posoleucel; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

DEADLINE: March 19, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/allovir-inc-loss-submission-form/?id=70851&from=4 

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ALVR during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 19, 2024. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com 
Phone: (646) 453-8903

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/class-action-filed-against-allovir-inc-alvr-seeking-recovery-for-investors--contact-the-gross-law-firm-302088602.html

SOURCE The Gross Law Firm

Copyright 2024 PR Newswire

1 Year AlloVir Chart

1 Year AlloVir Chart

1 Month AlloVir Chart

1 Month AlloVir Chart